Cost-Effectiveness of Quadrivalent Human Papillomavirus Vaccination in Adolescent Girls in Russian Federation

The human papillomavirus (HPV) infection is one of the major risk factor of development of genital warts, a cervical dysplasia, a cervical cancer, and also some other oncologic diseases. The usage  of quadrivalent HPV vaccine in girls reduces the corresponding case  rate and the mortality significantly.

The objective of this study is to analyze the cost-effectiveness of quadrivalent HPV vaccination cases of 12-year-old girls in Russian Federation.

Methods. A Markov model is used on the basis of epidemiological data in Russian Federation. In base case the cost-effectiveness was  estimated from societal perspective. We assumed that the effect of  vaccination remains throughout all life. The analysis is performed for survival of 12-year-old girls. We considered only effect in the  vaccinated population. Costs for therapy of the diseases associated  with HPV infection corresponded to compulsory health insurance  rates across St. Petersburg for 2017. Costs and life expectancy have been discounted for 3.5% a year.

Results. Quadrivalent HPV vaccination of 12-year-old girls in Russian Federation will allow to prevent counting on 100 000 the  vaccinated persons 2918 cases of genital warts, 5095 cases of  cervical dysplasia, 893 cases of invasive cervical cancer, 56 cases of  vulvar cancer, 18 cases of vaginal cancer, 13 cases of anal cancer, 7  cases of oropharyngeal cancer. The vaccination will provide cost  reduction, caused by HPV-associated diseases, for 453.9 million  rubles on 100 000 vaccinated, and 86.5% of the predicted prevented costs will be caused by decrease in incidence of cervical cancer, 9%  — cervical dysplasia, 2.9% — genital warts. The quadrivalent HPV vaccination is associated with an incremental cost-effectiveness ratio (ICER) of 247 560 rubles per quality adjusted life-year (QALY) and  334 200 rubles per life-year gained (LYG). Thus, in both cases, cost  effectiveness of rotavirus vaccination per 1 QALY will not exceed the  generally accepted threshold willingness-to-pay equal to three times  the gross domestic product in Russia (2016 — 1.76 million RUB).

Conclusions. Quadrivalent HPV vaccination of girls prior to the beginning of sex life could be considered in Russian Federation as an economically effective technology for preventing HPV-associated diseases.

1. La Vecchia C, Bosetti C, Lucchini F, et al. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975. Ann Oncol. 2010;21(6):1323–1360. doi: 10.1093/annonc/mdp530.

2. Клинышкова Т.В., Турчанинов Д.В., Самосудова И.Б. Эпидемиологические аспекты цервикального предрака у женского населения Омска (по материалам выборочного исследования) // Российский вестник акушера-гинеколога. — 2013. — Т.13. — №4. — С. 13–17. [Klinyshkova TV, Turchaninov DV, Samosudova IB. Epidemiological aspects of cervical precancer in a female population of Omsk (according to the data of a randomized study). Rossiiskii vestnik akushera-ginekologa. 2013;13(4):13–17. (In Russ).]

3. Злокачественные новообразования в России в 2014 году (заболеваемость и смертность) / Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. — М; 2016. — 250 с. [Zlokachestvennye novoobrazovaniya v Rossii v 2014 godu (zabolevaemost’ i smertnost’). Ed by Kaprin A.D., Starinskii V.V., Petrova G.V. Moscow; 2016. 250 p. (In Russ).]

4. Состояние онкологической помощи населению России в 2015 году / Под ред. А.Д. Каприна, В.В. Старинского, Г.В. Петровой. — М.; 2016. — 236 с. [Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii v 2015 godu. Ed by Kaprin A.D., Starinskii V.V., Petrova G.V. Moscow; 2016. 236 p. (In Russ).]

5. Костин А.А., Старинский В.В., Самсонов Ю.В., Асратов А.Т. Анализ статистических данных о злокачественных новообразованиях, ассоциированных с вирусом папилломы человека // Исследования и практика в медицине. — 2016. — Т.3. — №1 — С. 66–78. [Kostin AA, Starinskii VV, Samsonov YuV, Asratov AT. The analysis of statistical data on malignant neoplasms associated with human papillomavirus. Research’n Practical Medicine Journal. 2016;3(1):66–78. (In Russ).] doi: 10.17709/2409-2231-2016-3-1-9.

6. Шелякина Т.В., Леонов М.Г., Неродо Г.А. Онкоэпидемиологические аспекты оптимизации профилактики рака шейки матки // Кубанский научный медицинский вестник. — 2010. — №2 — С. 103–107. [Shelyakina TV, Leonov MG, Nerodo GA. Epidemiological aspects of optimization of prevention cervical cancer. Kubanskii nauchnyi meditsinskii vestnik. 2010;(2):103–107. (In Russ).]

7. Аксель Е.М. Состояние онкологической помощи населению России и стран СНГ в 2005 г. // Вестник Российского онкологического центра им. Н.Н. Блохина Российской академии медицинских наук. — 2007. — Т.18. — №S2 — С. 8–51. [Aksel’ EM. Sostoyanie onkologicheskoi pomoshchi naseleniyu Rossii i stran SNG v 2005 g. Journal of N.N. Blokhin Russian Cancer Research Center RAMS. 2007;18(S2):8–51. (In Russ).]

8. Урманчеева А.Ф. Эпидемиология рака вульвы. Факторы риска и прогноза // Практическая онкология. — 2006. — Т.7. — №4 — С. 189–196. [Urmancheeva AF. Epidemiologiya raka vul’vy. Faktory riska i prognoza. Prakticheskaya onkologiya. 2006;7(4):189–196. (In Russ).]

9. Leval A, Herweijer E, Ploner A, et al. Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study. J Natl Cancer Inst. 2013;105(7):469–474. doi: 10.1093/jnci/djt032.

10. Tabrizi SN, Brotherton JM, Kaldor JM, et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis. 2012;206(11):1645–1651. doi: 10.1093/infdis/jis590.

11. Шипулина О.Ю. Эпидемиологические особенности и меры профилактики онкогинекологической патологии папилломавирусной этиологии: Автореф. канд. дис. … канд. мед. наук. — М.; 2013. — 24 с. [Shipulina OYu. Epidemiologicheskie osobennosti i mery profilaktiki onkogineko-logicheskoi patologii papillomavirusnoi etiologii. [dissertation abstract] Moscow; 2013. 24 p. (In Russ).]

12. Boiron L, Joura E, Largeron N, et al. Estimating the costeffectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria. BMC Infect Dis. 2016;16:153. doi: 10.1186/s12879-016-1483-5.

13. Harper DM, DeMars LR. HPV vaccines — A review of the first decade. Gynecol Oncol. 2017;146(1):196–204. doi: 10.1016/j.ygyno.2017.04.004.

14. Smith GD, Travis L. Getting to know human papillomavirus (HPV) and the HPV vaccines. J Am Osteopath Assoc. 2011;111(3 Suppl 2):S29–34.

15. de Sanjose S, Serrano B, Castellsague X, et al. Human papillomavirus (HPV) and related cancers in the Global Alliance for Vaccines and Immunization (GAVI) countries. A WHO/ICO HPV Information Centre Report. Vaccine. 2012;30(Suppl 4):D1–D83. doi: 10.1016/S0264-410X(12)01435-1.

16. Jin XW, Lipold L, Sikon A, Rome E. Human papillomavirus vaccine: safe, effective, underused. Cleve Clin J Med. 2013;80(1):49–60. doi: 10.3949/ccjm.80a.12084.

17. Файзуллина Е.В. Папилломавирусная инфекция: современная точка зрения на проблeму // Практическая медицина. — 2009. — №5 — С. 12–20. [Faizullina EV. Papillomavirusnaya infektsiya: sovremennaya tochka zreniya na problemu. Prakticheskaya meditsina. 2009;(5):12–20. (In Russ).]

18. Wladysiuk M, Bebrysz M, Fedyna M, et al. Calculating indirect cost-differences caused by various approaches to unit costs. Results of move to work study (M2W). ISPOR 6th Asia- Pacific Conference. September 6–9, 2014; Beijing, China.

19. Труд и занятость в России. 2015. Статистический сборник Росстат. — M.; 2015. — 274 с. [Trud i zanyatost’ v Rossii. 2015. Statisticheskii sbornik Rosstat. Moscow; 2015. 274 p. (In Russ).]

20. World Health Organization. Macroeconomics and health: investing in health for economic development. Report of the WHO Commission on Macroeconomics and Health. Geneva, Switzerland: World Health Organization; 2001.